Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest & Investment Income: 2023-2024

Historic Interest & Investment Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $2.5 million.

  • Contineum Therapeutics' Interest & Investment Income rose 41.23% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.9 million, marking a year-over-year increase of 93.36%. This contributed to the annual value of $8.9 million for FY2024, which is 93.33% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Interest & Investment Income of $2.5 million as of Q4 2024, which was down 7.77% from $2.7 million recorded in Q3 2024.
  • In the past 5 years, Contineum Therapeutics' Interest & Investment Income ranged from a high of $2.7 million in Q3 2024 and a low of $401,000 during Q1 2023.
  • Its 2-year average for Interest & Investment Income is $1.7 million, with a median of $1.8 million in 2023.
  • Data for Contineum Therapeutics' Interest & Investment Income shows a peak YoY spiked of 307.98% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Contineum Therapeutics' Interest & Investment Income stood at $1.8 million in 2023, then surged by 41.23% to $2.5 million in 2024.
  • Its Interest & Investment Income was $2.5 million in Q4 2024, compared to $2.7 million in Q3 2024 and $2.0 million in Q2 2024.